Review of 30 Studies Finds Thymosin Raised Some Immune Counts in Colorectal Cancer Patients but Evidence Is Too Weak for Routine Use
Researchers at the First Affiliated Hospital of Henan University of Chinese Medicine reviewed 30 studies with 2,514 colorectal cancer patients, including 25 randomized trials, in which thymosin preparations were added to the same anticancer treatment, publishing in Frontiers in Oncology. After surgery, thymosin was linked to higher CD4 percentages, CD4/CD8 ratios, and natural killer cell percentages, and some trials reported better performance scores, but effects on neutropenia were inconclusive and only one trial gave comparable survival data. Certainty was low or very low, and the authors say current evidence does not support routine use.